08 August 2019 | News
Entering into infectious disease genetics and collaborating with XCyton Diagnostics
(L-R)- Dr VL Ramprasad, Dr B V Ravikumar, Dr V Ravi
MedGenome Labs, leader in clinical data driven genetic diagnostics and drug discovery research in India, has developed ‘SPIT SEQ’, the first Whole Genome Sequencing based test that can provide a detailed analysis of every single mutation present in any tuberculosis (TB) bacteria causing drug resistance (DR) directly from the sputum. This break-through will enable a doctor to quickly and accurately prescribe the most effective drug to a tuberculosis patient without a trial and error process, followed currently that takes a month.
This test has been validated with over 100 samples where it recorded with 100% sensitivity and 98.04 % specificity when compared with Line Probe Assay (LPA). 50 out of those samples were in association with P.D. Hinduja Hospital and Medical Research Centre, Mumbai. A manuscript is under review for publication.
“SPIT SEQ is a massive breakthrough that can help millions. This particular test not only brings accurate results but also saves a lot of time where TB treatment is concerned. In lines with India’s objective to counter TB effectively and quickly, we aim to benefit the last person living with TB today. The test is prices at Rs 7500 currently but we hope bring down the price later on. We have collaborated with the National Tuberculosis Institute and we will be studing 500-1000 cases for the next 1 year using SPIT SEQ.”, said Dr VL Ramprasad, COO, MedGenome Labs